Quanterix CORP Form 4 insider transactions

Quanterix Corp CEO Masoud Toloue disposed of 247 shares of common stock on February 28, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Quanterix emphasizes the strategic and financial advantages of acquiring Akoya Biosciences, projecting significant market expansion and synergy generation, while addressing concerns raised by Kent Lake Partners regarding director nominations.

Quanterix Corporation announces the expiration of the Hart-Scott-Rodino Act waiting period related to its proposed merger with Akoya Biosciences, moving the acquisition closer to completion.

Vandana Sriram, CFO of Quanterix Corp, reports the disposal of 92 common stock shares to cover tax obligations upon the vesting of restricted stock units.

Quanterix Corp CEO Masoud Toloue disposed of shares to cover tax obligations arising from the vesting of restricted stock units.

Quanterix Corporation announces its proposed acquisition of Akoya Biosciences, aiming to expand its market reach into immunology and oncology while accelerating growth and profitability.

Vandana Sriram, Chief Financial Officer of Quanterix Corp, acquired shares and stock options on February 4, 2025, according to a recent SEC Form 4 filing.

Masoud Toloue, President and CEO of Quanterix Corp, reports acquisition of common stock and stock options.

Vandana Sriram, CFO of Quanterix Corp, disposed of shares to cover tax obligations arising from the vesting of restricted stock units.

Masoud Toloue, President and CEO of Quanterix Corp, reported the disposal of common stock to cover tax obligations arising from the vesting of restricted stock units (RSUs).

Quanterix CFO Vandana Sriram disposed of 93 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Masoud Toloue, President and CEO of Quanterix Corp, disposed of 906 shares of common stock on January 15, 2025, to cover tax obligations arising from the vesting of restricted stock units.

Quanterix's CEO presented at the J.P. Morgan Healthcare Conference, outlining the pending merger with Akoya Biosciences and its anticipated benefits, including significant cost synergies and revenue growth.

Quanterix reports preliminary Q4 2024 revenue of $34.9 million and full year 2024 revenue of $137.2 million, representing 12% year-over-year growth for the full year, and discusses the pending acquisition of Akoya Biosciences.

Quanterix is set to acquire Akoya Biosciences in a stock-for-stock transaction aimed at creating a leader in biomarker detection across blood and tissue.

Quanterix will acquire Akoya Biosciences in an all-stock transaction, creating the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.

Director David R Walt reports acquisition of common stock and stock options in Quanterix Corp.

Director Ivana Magovcevic-Liebisch acquired shares and stock options in Quanterix Corp on January 2, 2025, according to a recent SEC filing.

Director Martin D. Madaus of Quanterix Corp reports acquisition of restricted stock units and stock options, along with indirect holdings through a trust.

Director Jeffrey Thomas Elliott acquired shares and stock options in Quanterix Corp on January 2, 2025, according to a recent SEC filing.

Director Karen Flynn of Quanterix Corp. acquired 7,435 shares of common stock and 15,821 stock options on January 2, 2025.

Director Paul M. Meister reports acquisition of common stock and stock options in Quanterix Corp.

Director Sarah E. Hlavinka of Quanterix Corp. reports acquisition of common stock and stock options, including restricted stock units, on January 2, 2025.

Director William P. Donnelly of Quanterix Corp. reports acquiring shares and stock options, including restricted stock units, on January 2, 2025.

Quanterix CEO Masoud Toloue sold 415 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Quanterix CEO Masoud Toloue sold 752 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Vandana Sriram, CFO of Quanterix Corp, reports a transaction involving the withholding of shares to cover tax obligations.

Quanterix CEO Masoud Toloue sold 368 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Quanterix CEO Masoud Toloue sold 1,120 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Quanterix CFO, Vandana Sriram, sold 78 shares of common stock to cover tax obligations related to the vesting of restricted stock units.